Sidoti Csr Cuts Earnings Estimates for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at Sidoti Csr cut their FY2024 earnings per share (EPS) estimates for USANA Health Sciences in a research report issued to clients and investors on Wednesday, October 23rd. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $2.45 for the year, down from their previous estimate of $2.48. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.73 EPS, Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.64 EPS, Q4 2025 earnings at $0.75 EPS, FY2025 earnings at $2.74 EPS, Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.74 EPS, Q3 2026 earnings at $0.77 EPS and FY2026 earnings at $3.20 EPS.

Several other brokerages have also recently issued reports on USNA. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th. DA Davidson reduced their price objective on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a research note on Wednesday.

USANA Health Sciences Stock Up 6.1 %

Shares of NYSE:USNA opened at $36.58 on Thursday. USANA Health Sciences has a 52-week low of $34.15 and a 52-week high of $55.45. The stock has a market cap of $696.85 million, a price-to-earnings ratio of 12.93, a PEG ratio of 1.15 and a beta of 0.89. The business has a 50-day moving average price of $37.98 and a 200-day moving average price of $42.55.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.80% and a net margin of 6.30%. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. During the same quarter last year, the company earned $0.59 earnings per share.

Insider Activity at USANA Health Sciences

In related news, Director John Turman Fleming sold 1,000 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares in the company, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the sale, the director now directly owns 2,503 shares in the company, valued at $111,208.29. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert A. Fuller sold 674 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,940 shares of company stock worth $311,670. 0.33% of the stock is owned by corporate insiders.

Institutional Trading of USANA Health Sciences

Institutional investors have recently made changes to their positions in the company. BOKF NA boosted its stake in shares of USANA Health Sciences by 274.5% in the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after acquiring an additional 2,031 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of USANA Health Sciences by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after acquiring an additional 494 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of USANA Health Sciences by 4.4% in the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock worth $292,000 after acquiring an additional 322 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of USANA Health Sciences in the second quarter worth approximately $340,000. Finally, DGS Capital Management LLC boosted its stake in shares of USANA Health Sciences by 61.8% in the first quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock worth $352,000 after acquiring an additional 2,773 shares during the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.